The RefleXion® X1 is the only dual-treatment modality platform with near diagnostic quality kVCT imaging that delivers both breakthrough SCINTIX® therapy and IMRT, SBRT and SRS. With reimbursement and product support services designed for freestanding cancer centers, the X1 can serve as the backbone to your practice.
Download White Paper
The Centers for Medicare and Medicaid (CMS) expanded reimbursement of SCINTIX therapy to include freestanding cancer centers effective January 1, 2025. This breakthrough technology is now an option for the ~40% of Americans receiving radiation therapy in freestanding centers1. CMS also introduced a professional payment coding mechanism to support physician adoption of SCINTIX therapy.
The X1 platform with SCINTIX therapy treats multiple tumors in a single treatment plan to streamline the workflow and enable efficient treatment of incremental patients with metastatic disease. A hybrid, multi-target treatment (MTT)2 plan can include SBRT tumors and a SCINTIX therapy tumor.
SCINTIX technology automates targeting and motion management for both expected and unexpected shifts, such as patient movement, so when the tumor moves, the dose automatically moves too. And early clinical cases have demonstrated up to 50% reduction3 in the volume treated with SCINTIX therapy, sparing more healthy tissue.
The RefleXion X1 delivers conventional radiotherapy (IMRT, SBRT, SRS) guided by state-of-the-art kVCT imaging and is cleared for all solid tumors, while SCINTIX therapy is cleared to treat lung and bone tumors arising from primary or metastatic disease. This versatile platform is designed to fit in your existing LINAC vault with minimum shielding requirements to streamline implementation costs.
1 https://docs.house.gov/meetings/IF/IF14/20171108/106599/HHRG-115-IF14-Wstate-KavanaghB-20171108.pdf
2 Multi-target treatments (MTT) are integrated into the FDA-cleared SCINTIX therapy indications for use workflow. MTT enhances dose optimization
review for delivery to more than one target.
3 Individual results may vary.
Let us tell you more.
Contact UsStay up to date.
Sign Up